BeStock  
Stocks › Biotechnology › LXRX

Lexicon Pharmaceuticals LXRX

US equityMarket cap rank #3424Biotechnology
$1.76 +$0.01 (+0.57%)
Pre-market · Oct 8, 9:00 am ET · After hours $1.76 0.00%
Open$1.73
Prev close$1.75
Day range$1.71 – $1.77
Volume1.10M
Market cap$783.12M
P/E (TTM)–
Dividend yield–

Earnings

Average move on report day±8.1%last 16 reports
Closed higher9 of 1656% of the time
Best reaction+22.9%
Worst reaction-16.1%

Stock move on the day after each report

-2.6%2023/Q2-8.8%2023/Q3+2.4%2024/Q1-16.1%2024/Q2-8.4%2024/Q3+6.6%2024/Q4-15.6%2025/Q1+9.5%2025/Q2+3.6%2025/Q3+0.6%2025/Q4+5.0%2026/Q1-3.7%2026/Q2
QuarterReport dateTimingImplied moveActual moveVersus implied
2026/Q26 Aug 2026Pre Market±24.3%-3.67%Within range
2026/Q17 May 2026Pre Market±18.8%+5.00%Within range
2025/Q45 Mar 2026Pre Market±24.5%+0.61%Within range
2025/Q36 Nov 2025Pre Market±39.9%+3.62%Within range
2025/Q26 Aug 2025Pre Market±35.7%+9.52%Within range
2025/Q113 May 2025After Market±36.5%-15.57%Within range
2024/Q46 Mar 2025After Market±62.6%+6.55%Within range
2024/Q312 Nov 2024After Market±37.2%-8.40%Within range
2024/Q21 Aug 2024After Market±21.1%-16.09%Within range
2024/Q12 May 2024After Market±17.6%+2.35%Within range
2023/Q38 Nov 2023Pre Market±104.0%-8.80%Within range
2023/Q23 Aug 2023After Market±18.2%-2.60%Within range
2023/Q12 May 2023After Market±23.9%+15.13%Within range
2022/Q42 Mar 2023After Market±14.2%+22.94%Bigger than priced
2022/Q39 Nov 2022Pre Market±14.6%-4.85%Within range
2022/Q22 Aug 2022After Market±30.5%+3.46%Within range

"Implied move" is the size of move the options market was pricing ahead of the report. Move is the stock’s change on the first session after the release.

Latest reported quarter: Q2, ended Jun 2026

Revenue$692,000.00-97.6% YoY
Operating profit-$26.54M-810.4% YoY
Net profit-$31.78M-1,077.1% YoY
Diluted EPS-$0.07-800.0% YoY
Free cash flow-$9.19M-154.1% YoY
Operating cash flow-$9.19M

Revenue, last 8 quarters

$1.8MSep '24$26.6MDec '24$1.3MMar '25$28.9MJun '25$14.2MSep '25$5.5MDec '25$21.1MMar '26$692.0KJun '26

Net profit, last 8 quarters

$-64.8MSep '24$-33.8MDec '24$-25.3MMar '25$3.3MJun '25$-12.8MSep '25$-15.5MDec '25$-1.0MMar '26$-31.8MJun '26

Profitability & balance sheet

Gross margin99.1%
Operating margin-131.4%
Net margin-147.4%
Return on equity-40.2%
Return on assets-25.7%
Return on invested capital-28.0%
Current ratio13.37
Liabilities / assets30.2%
Cash & investments$190.61M
Total debt$57.64M
Net cash (debt)$132.97M

Discussion

No comments yet — be the first to weigh in on LXRX.

Leave a comment

Scroll to Top